BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Ellison EC, Bloomston M, Bekaii-Saab T. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015;22:1153-1159. [PMID: 25358667 DOI: 10.1245/s10434-014-4225-1] [Cited by in Crossref: 158] [Cited by in F6Publishing: 134] [Article Influence: 19.8] [Reference Citation Analysis]
Number Citing Articles
1 Loehrer AP, Kinnier CV, Ferrone CR. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma. Adv Surg 2016;50:115-28. [PMID: 27520867 DOI: 10.1016/j.yasu.2016.03.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
2 Koay EJ, Katz MHG, Wang H, Wang X, Prakash L, Javle M, Shroff R, Fogelman D, Avila S, Zaid M, Elganainy D, Lee Y, Crane CH, Krishnan S, Das P, Fleming JB, Lee JE, Tamm EP, Bhosale P, Lee JH, Weston B, Maitra A, Wolff RA, Varadhachary GR. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. JCO Precis Oncol 2019;3:PO. [PMID: 32914036 DOI: 10.1200/PO.19.00001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Lombardi P, Silvestri S, Marino D, Santarelli M, Campra D, De Paolis P, Aglietta M, Leone F. “Shades of Gray” in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria. Critical Reviews in Oncology/Hematology 2019;133:17-24. [DOI: 10.1016/j.critrevonc.2018.10.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Rangelova E, Wefer A, Persson S, Valente R, Tanaka K, Orsini N, Segersvärd R, Arnelo U, Del Chiaro M. Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience. Annals of Surgery 2021;273:579-86. [DOI: 10.1097/sla.0000000000003301] [Cited by in Crossref: 36] [Cited by in F6Publishing: 16] [Article Influence: 12.0] [Reference Citation Analysis]
5 Kozak GM, Epstein JD, Deshmukh SP, Scott BB, Keith SW, Lavu H, Yeo CJ, Winter JM. Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer. J Gastrointest Surg 2018;22:288-94. [PMID: 29139084 DOI: 10.1007/s11605-017-3595-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
6 Ueda A, Sakai N, Yoshitomi H, Furukawa K, Takayashiki T, Kuboki S, Takano S, Suzuki D, Kagawa S, Mishima T, Nakadai E, Miyazaki M, Ohtsuka M. Is hepatic artery coil embolization useful in distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic cancer? World J Surg Oncol 2019;17:124. [PMID: 31315628 DOI: 10.1186/s12957-019-1667-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
7 Matsumoto Y, Fukumitsu N, Ishikawa H, Nakai K, Sakurai H. A Critical Review of Radiation Therapy: From Particle Beam Therapy (Proton, Carbon, and BNCT) to Beyond. J Pers Med 2021;11:825. [PMID: 34442469 DOI: 10.3390/jpm11080825] [Reference Citation Analysis]
8 Sugumar K, Hue JJ, Hardacre JM, Ammori JB, Rothermel LD, Dorth J, Saltzman J, Mohamed A, Selfridge JE, Bajor D, Winter JM, Ocuin LM. Combined multiagent chemotherapy and radiotherapy is associated with prolonged overall survival in patients with non-operatively managed stage II-III pancreatic adenocarcinoma. HPB (Oxford) 2021:S1365-182X(21)01582-3. [PMID: 34465529 DOI: 10.1016/j.hpb.2021.08.938] [Reference Citation Analysis]
9 Yokota T, Takano S, Yoshitomi H, Kagawa S, Furukawa K, Takayashiki T, Kuboki S, Suzuki D, Sakai N, Nojima H, Mishima T, Nakadai E, Ohtsuka M. Successful treatment of a locally advanced unresectable pancreatic cancer patient with interstitial pneumonitis by conversion surgery following gemcitabine plus nab-paclitaxel chemotherapy: A case report. Mol Clin Oncol 2019;10:419-24. [PMID: 30931110 DOI: 10.3892/mco.2019.1807] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Gemenetzis G, Groot VP, Blair AB, Laheru DA, Zheng L, Narang AK, Fishman EK, Hruban RH, Yu J, Burkhart RA, Cameron JL, Weiss MJ, Wolfgang CL, He J. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Ann Surg 2019;270:340-7. [PMID: 29596120 DOI: 10.1097/SLA.0000000000002753] [Cited by in Crossref: 92] [Cited by in F6Publishing: 46] [Article Influence: 46.0] [Reference Citation Analysis]
11 Matsumoto I, Kamei K, Omae K, Suzuki S, Matsuoka H, Mizuno N, Ozaka M, Ueno H, Kobayashi S, Uesugi K, Kobayashi M, Todaka A, Fukutomi A. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan. Pancreatology 2019;19:296-301. [PMID: 30638853 DOI: 10.1016/j.pan.2019.01.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
12 Creasy JM, Goldman DA, Gonen M, Dudeja V, Askan G, Basturk O, Balachandran VP, Allen PJ, DeMatteo RP, D'Angelica MI, Jarnagin WR, Peter Kingham T. Predicting Residual Disease in Incidental Gallbladder Cancer: Risk Stratification for Modified Treatment Strategies. J Gastrointest Surg 2017;21:1254-61. [PMID: 28484891 DOI: 10.1007/s11605-017-3436-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
13 Hank T, Strobel O. Conversion Surgery for Advanced Pancreatic Cancer. J Clin Med 2019;8:E1945. [PMID: 31718103 DOI: 10.3390/jcm8111945] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
14 Maggino L, Vollmer CM Jr. Recent Advances in Pancreatic Cancer Surgery. Curr Treat Options Gastroenterol 2017;15:520-37. [PMID: 28852967 DOI: 10.1007/s11938-017-0150-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
15 Berger AK, Haag GM, Ehmann M, Byl A, Jäger D, Springfeld C. Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient. BMC Gastroenterol 2017;17:143. [PMID: 29207968 DOI: 10.1186/s12876-017-0709-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
16 Lu 2nd, Kwon D, Chalikonda S, Sellers M, Kotz E, Scoggins C, McMasters KM, Watkins K. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg. 2015;262:486-94; discussion 492-4. [PMID: 26258317 DOI: 10.1097/sla.0000000000001441] [Cited by in Crossref: 222] [Cited by in F6Publishing: 96] [Article Influence: 31.7] [Reference Citation Analysis]
17 Einama T, Kamachi H, Tsuruga Y, Sakata T, Shibuya K, Sakamoto Y, Shimada S, Wakayama K, Orimo T, Yokoo H, Kamiyama T, Katoh N, Uchinami Y, Mitsuhashi T, Taketomi A. Optimal resection area for superior mesenteric artery nerve plexuses after neoadjuvant chemoradiotherapy for locally advanced pancreatic carcinoma. Medicine (Baltimore) 2018;97:e11309. [PMID: 30075497 DOI: 10.1097/MD.0000000000011309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Kobayashi S, Ueno M, Omae K, Kuramochi H, Terao M, Mizuno N, Ozaka M, Ueno H, Uesugi K, Kobayashi N, Kobayashi M, Todaka A, Fukutomi A. Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer. Oncotarget 2019;10:1775-84. [PMID: 30956757 DOI: 10.18632/oncotarget.26633] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
19 Keane FK, Wo JY, Ferrone CR, Clark JW, Blaszkowsky LS, Allen JN, Kwak EL, Ryan DP, Lillemoe KD, Fernandez-del Castillo C, Hong TS. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. American Journal of Clinical Oncology 2018;41:607-12. [DOI: 10.1097/coc.0000000000000336] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
20 Attiyeh MA, Amini A, Chung V, Melstrom LG. Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King. J Surg Oncol 2021;123:1395-404. [PMID: 33831247 DOI: 10.1002/jso.26415] [Reference Citation Analysis]
21 Yamada Y, Fujii H, Watanabe D, Kato-Hayashi H, Ohata K, Kobayashi R, Ishihara T, Uemura S, Iwashita T, Shimizu M, Suzuki A. Severe Neutropenia is Associated with Better Clinical Outcomes in Patients with Advanced Pancreatic Cancer Who Receive Modified FOLFIRINOX Therapy. Cancers (Basel). 2018;10. [PMID: 30453583 DOI: 10.3390/cancers10110454] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
22 Feng M, Cao Z, Sun Z, Zhang T, Zhao Y. Pancreatic head cancer: Open or minimally invasive pancreaticoduodenectomy? Chin J Cancer Res 2019;31:862-77. [PMID: 31949389 DOI: 10.21147/j.issn.1000-9604.2019.06.03] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Adamu M, Nitschke P, Petrov P, Rentsch A, Distler M, Reissfelder C, Welsch T, Saeger H, Weitz J, Rahbari NN. Validation of prognostic risk scores for patients undergoing resection for pancreatic cancer. Pancreatology 2018;18:585-91. [DOI: 10.1016/j.pan.2018.05.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
24 Del Chiaro M, Rangelova E, Halimi A, Ateeb Z, Scandavini C, Valente R, Segersvärd R, Arnelo U, Verbeke CS. Pancreatectomy with arterial resection is superior to palliation in patients with borderline resectable or locally advanced pancreatic cancer. HPB (Oxford) 2019;21:219-25. [PMID: 30093144 DOI: 10.1016/j.hpb.2018.07.017] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
25 Hackert T, Sachsenmaier M, Hinz U, Schneider L, Michalski CW, Springfeld C, Strobel O, Jäger D, Ulrich A, Büchler MW. Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients. Annals of Surgery 2016;264:457-63. [DOI: 10.1097/sla.0000000000001850] [Cited by in Crossref: 235] [Cited by in F6Publishing: 91] [Article Influence: 39.2] [Reference Citation Analysis]
26 Takeda T, Sasaki T, Mie T, Furukawa T, Yamada Y, Kasuga A, Matsuyama M, Ozaka M, Sasahira N. The prognostic impact of tumour location and first-line chemotherapy regimen in locally advanced pancreatic cancer. Jpn J Clin Oncol 2021;51:728-36. [PMID: 33611490 DOI: 10.1093/jjco/hyab014] [Reference Citation Analysis]
27 Hyun JJ, Rose JB, Alseidi AA, Biehl TR, Helton S, Coy DL, Kozarek RA, Rocha FG. Significance of radiographic splenic vessel involvement in the pancreatic ductal adenocarcinoma of the body and tail of the gland. J Surg Oncol 2019;120:262-9. [PMID: 31093997 DOI: 10.1002/jso.25498] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
28 Yamao K, Takenaka M, Yoshikawa T, Ishikawa R, Okamoto A, Yamazaki T, Nakai A, Omoto S, Kamata K, Minaga K, Hagiwara S, Sakurai T, Nishida N, Chiba Y, Watanabe T, Kudo M. Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study. Intern Med 2019;58:1993-2002. [PMID: 30996164 DOI: 10.2169/internalmedicine.2234-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
29 Tanaka Y, Soda H, Fukuda Y, Nio K, Ono S, Tomono H, Shimada M, Yoshida M, Harada T, Umemura A, Iwasaki K, Yamaguchi H, Mukae H. Vildagliptin-induced ground-glass nodules mimicking lung metastases in a cancer patient receiving Lactobacillus probiotic supplementation. Thorac Cancer 2020;11:470-4. [PMID: 31908161 DOI: 10.1111/1759-7714.13292] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
30 Gostimir M, Bennett S, Moyana T, Sekhon H, Martel G. Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review. BMC Cancer 2016;16:786. [PMID: 27724927 DOI: 10.1186/s12885-016-2821-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
31 Mace TA, Shakya R, Elnaggar O, Wilson K, Komar HM, Yang J, Pitarresi JR, Young GS, Ostrowski MC, Ludwig T, Bekaii-Saab T, Bloomston M, Lesinski GB. Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer. Oncotarget 2015;6:44509-22. [PMID: 26575024 DOI: 10.18632/oncotarget.6332] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
32 Shaib WL, Sayegh L, Zhang C, Belalcazar A, Ip A, Alese OB, Akce M, Wu C, Qu Y, Maithel SK, Kooby D, Cardona K, Sarmeinto JM, El-Rayes BF. Induction Therapy in Localized Pancreatic Cancer. Pancreas 2019;48:913-9. [PMID: 31268982 DOI: 10.1097/MPA.0000000000001353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Nanda RH, El-Rayes B, Maithel SK, Landry J. Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. J Surg Oncol. 2015;111:1028-1034. [PMID: 26073887 DOI: 10.1002/jso.23921] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 6.7] [Reference Citation Analysis]
34 Zhang B, Lee GC, Qadan M, Fong ZV, Mino-Kenudson M, Desphande V, Malleo G, Maggino L, Marchegiani G, Salvia R, Scarpa A, Luchini C, De Gregorio L, Ferrone CR, Warshaw AL, Lillemoe KD, Bassi C, Castillo CF. Revision of Pancreatic Neck Margins Based on Intraoperative Frozen Section Analysis Is Associated With Improved Survival in Patients Undergoing Pancreatectomy for Ductal Adenocarcinoma. Ann Surg 2021;274:e134-42. [PMID: 31851002 DOI: 10.1097/SLA.0000000000003503] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
35 Nishio K, Kimura K, Amano R, Yamazoe S, Ohrira G, Nakata B, Hirakawa K, Ohira M. Preoperative predictors for early recurrence of resectable pancreatic cancer. World J Surg Oncol 2017;15:16. [PMID: 28069033 DOI: 10.1186/s12957-016-1078-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
36 Kim JH, Lee SC, Oh SY, Song SY, Lee N, Nam EM, Lee S, Hwang IG, Lee HR, Lee KT, Bae SB, Kim HJ, Jang JS, Lim DH, Lee HW, Kang SY, Kang JH. Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study.Cancer Commun (Lond). 2018;38:32. [PMID: 29866170 DOI: 10.1186/s40880-018-0304-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
37 Bolton NM, Maerz AH, Brown RE, Bansal M, Bolton JS, Conway WC. Multiagent neoadjuvant chemotherapy and tumor response are associated with improved survival in pancreatic cancer. HPB 2019;21:413-8. [DOI: 10.1016/j.hpb.2018.08.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Groot Koerkamp B. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. J Natl Cancer Inst 2019;111:782-94. [PMID: 31086963 DOI: 10.1093/jnci/djz073] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 38.5] [Reference Citation Analysis]
39 Charalambous P, Moris D, Karachaliou GS, Papalampros A, Dimitrokallis N, Tsilimigras DI, Oikonomou D, Petrou A. The efficacy and safety of the open approach irreversible electroporation in the treatment of pancreatic cancer: A systematic review. Eur J Surg Oncol 2020;46:1565-72. [PMID: 32536525 DOI: 10.1016/j.ejso.2020.05.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
40 Pietrasz D, Turrini O, Vendrely V, Simon J, Hentic O, Coriat R, Portales F, Le Roy B, Taieb J, Regenet N, Goere D, Artru P, Vaillant J, Huguet F, Laurent C, Sauvanet A, Delpero J, Bachet JB, Sa Cunha A. How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort. Ann Surg Oncol 2019;26:109-17. [DOI: 10.1245/s10434-018-6931-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
41 Karunakaran M, Barreto SG. Surgery for pancreatic cancer: current controversies and challenges. Future Oncol 2021. [PMID: 34747183 DOI: 10.2217/fon-2021-0533] [Reference Citation Analysis]
42 Reni M, Balzano G, Zanon S, Passoni P, Nicoletti R, Arcidiacono PG, Pepe G, Doglioni C, Fugazza C, Ceraulo D, Falconi M, Gianni L. Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma. Br J Cancer. 2016;115:290-296. [PMID: 27404453 DOI: 10.1038/bjc.2016.209] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
43 McIntyre CA, Cohen NA, Goldman DA, Gonen M, Sadot E, O'Reilly EM, Varghese AM, Yu KH, Balachandran VP, Soares KC, D'Angelica MI, Drebin JA, Kingham TP, Allen PJ, Wei AC, Jarnagin WR. Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. J Surg Oncol 2021. [PMID: 34719035 DOI: 10.1002/jso.26735] [Reference Citation Analysis]
44 Vienot A, Chevalier H, Bolognini C, Gherga E, Klajer E, Meurisse A, Jary M, Kim S, d’Engremont C, Nguyen T, Calcagno F, Almotlak H, Fein F, Nasri M, Abdeljaoued S, Turpin A, Borg C, Vernerey D. FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study. World J Gastrointest Oncol 2020; 12(3): 332-346 [PMID: 32206183 DOI: 10.4251/wjgo.v12.i3.332] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Wei AC, Ou FS, Shi Q, Carrero X, O'Reilly EM, Meyerhardt J, Wolff RA, Kindler HL, Evans DB, Deshpande V, Misdraji J, Tamm E, Sahani D, Moore M, Newman E, Merchant N, Berlin J, Goff LW, Pisters P, Posner MC. Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol 2019;26:4489-97. [PMID: 31418130 DOI: 10.1245/s10434-019-07685-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
46 Li X, Guo C, Li Q, Wei S, Zhang Q, Chen Y, Shen Y, Ma T, Li G, Gao S, Que R, Lou J, Yu R, Yuan Y, Wei Q, Huang P, Liang T, Bai X. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population. Oncologist 2019;24:301-e93. [PMID: 30459238 DOI: 10.1634/theoncologist.2018-0696] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
47 Soweid AM. The borderline resectable and locally advanced pancreatic ductal adenocarcinoma: Definition. Endosc Ultrasound 2017;6:S76-8. [PMID: 29387696 DOI: 10.4103/eus.eus_66_17] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
48 Golan T, Khvalevsky EZ, Hubert A, Gabai RM, Hen N, Segal A, Domb A, Harari G, David EB, Raskin S, Goldes Y, Goldin E, Eliakim R, Lahav M, Kopleman Y, Dancour A, Shemi A, Galun E. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget. 2015;6:24560-24570. [PMID: 26009994 DOI: 10.18632/oncotarget.4183] [Cited by in Crossref: 139] [Cited by in F6Publishing: 134] [Article Influence: 23.2] [Reference Citation Analysis]
49 Nitsche U, Wenzel P, Siveke JT, Braren R, Holzapfel K, Schlitter AM, Stöß C, Kong B, Esposito I, Erkan M, Michalski CW, Friess H, Kleeff J. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience. Ann Surg Oncol 2015;22 Suppl 3:S1212-20. [PMID: 26350368 DOI: 10.1245/s10434-015-4851-2] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 7.9] [Reference Citation Analysis]
50 Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Nakagawa N, Okada K, Takahashi S, Sueda T. Prognostic impact of normalization of serum tumor markers following neoadjuvant chemotherapy in patients with borderline resectable pancreatic carcinoma with arterial contact. Cancer Chemother Pharmacol 2017;79:801-11. [PMID: 28314992 DOI: 10.1007/s00280-017-3281-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
51 Enzler T, Bates S. Clinical Trials in Pancreatic Cancer: A Long Slog. Oncologist 2017;22:1424-6. [PMID: 28982802 DOI: 10.1634/theoncologist.2017-0453] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
52 Chen Z, Lv Y, Li H, Diao R, Zhou J, Yu T. Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer. Medicine (Baltimore) 2021;100:e24068. [PMID: 33546009 DOI: 10.1097/MD.0000000000024068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
53 Fromer MW, Hawthorne J, Philips P, Egger ME, Scoggins CR, McMasters KM, Martin RCG. An Improved Staging System for Locally Advanced Pancreatic Cancer: A Critical Need in the Multidisciplinary Era. Ann Surg Oncol 2021. [PMID: 34089107 DOI: 10.1245/s10434-021-10174-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Bhutiani N, Li Y, Zheng Q, Pandit H, Shi X, Chen Y, Yu Y, Pulliam ZR, Tan M, Martin RCG. Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma. Ann Surg Oncol 2020;27:4348-59. [DOI: 10.1245/s10434-020-08782-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
55 Saito K, Nakai Y, Isayama H, Yamamoto R, Kawakubo K, Kodama Y, Katanuma A, Kanno A, Itonaga M, Koike K. A Prospective Multicenter Study of Partially Covered Metal Stents in Patients Receiving Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Cancer: BTS-NAC Study. Gut Liver 2021;15:135-41. [PMID: 32340436 DOI: 10.5009/gnl19302] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
56 Joo I, Lee JM, Lee ES, Ahn SJ, Lee DH, Kim S, Ryu JK, Oh D, Kim K, Lee K, Jang J. Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy. American Journal of Roentgenology 2018;210:1059-65. [DOI: 10.2214/ajr.17.18310] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
57 Motoi F, Satoi S, Honda G, Wada K, Shinchi H, Matsumoto I, Sho M, Tsuchida A, Unno M; Study Group of Preoperative therapy for Pancreatic cancer (PREP). A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. J Gastroenterol 2019;54:194-203. [PMID: 30182219 DOI: 10.1007/s00535-018-1506-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
58 Bian Y, Jiang H, Ma C, Cao K, Fang X, Li J, Wang L, Zheng J, Lu J. Performance of CT-based radiomics in diagnosis of superior mesenteric vein resection margin in patients with pancreatic head cancer. Abdom Radiol (NY). 2020;45:759-773. [PMID: 31932878 DOI: 10.1007/s00261-019-02401-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
59 Palmarocchi MC, Balzarotti Canger RC, Saletti P. Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report. Oncol Lett 2017;13:4445-52. [PMID: 28588713 DOI: 10.3892/ol.2017.6026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
60 Yang L, Bai Y, Li Q, Chen J, Liu F, Weng X, Xu F. Analysis of the Curative Effect of Neoadjuvant Therapy on Pancreatic Cancer. Front Oncol 2021;11:695645. [PMID: 34485131 DOI: 10.3389/fonc.2021.695645] [Reference Citation Analysis]
61 Parekh HD, Starr J, George TJ Jr. The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma. Curr Treat Options Oncol 2017;18:73. [PMID: 29143898 DOI: 10.1007/s11864-017-0515-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
62 Paik WH, Kim YT. The Author's Response: Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer. J Korean Med Sci 2016;31:1505-6. [PMID: 27510399 DOI: 10.3346/jkms.2016.31.9.1505] [Reference Citation Analysis]
63 Rombouts S, Walma M, Vogel JA, Rijssen Lv, Wilmink J, Mohammad NH, Santvoort Hv, Molenaar IQ, Besselink MG Systematic review of resection rates and clinical outcomes after FOLFIRINOX-based treatment in patients with locally advanced pancreatic cancer. American Society of Clinical Oncology Annual Meeting. 2016;suppl: abstr 4115. [PMID: 27370653 DOI: 10.1245/s10434-016-5373-2] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 13.2] [Reference Citation Analysis]
64 Xu X, Wu Q, Wang Z, Zheng S, Ge K, Jia C. Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer. Clin Exp Med 2019;19:149-57. [PMID: 30498929 DOI: 10.1007/s10238-018-0540-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
65 Tong H, Fan Z, Liu B, Lu T. The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. Sci Rep. 2018;8:8666. [PMID: 29875415 DOI: 10.1038/s41598-018-26811-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
66 Khushman M, Dempsey N, Cudris Maldonado J, Loaiza-bonilla A, Velez M, Carcas L, Dammrich D, Hurtado-cordovi J, Parajuli R, Pollack T, Harwood AP, Macintyre J, Tzeng CD, Merchan JR, Restrepo MH, Akunyili II, Ribeiro A, Narayanan G, Portelance L, Sleeman D, Levi JU, Rocha Lima CM, Hosein PJ. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Pancreatology 2015;15:667-73. [DOI: 10.1016/j.pan.2015.08.010] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 7.7] [Reference Citation Analysis]
67 Chllamma MK, Cook N, Dhani NC, Giby K, Dodd A, Wang L, Hedley DW, Moore MJ, Knox JJ. FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. Br J Cancer. 2016;115:649-654. [PMID: 27467054 DOI: 10.1038/bjc.2016.222] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
68 Cui SJ, Tang TY, Zou XW, Su QM, Feng L, Gong XY. Role of imaging biomarkers for prognostic prediction in patients with pancreatic ductal adenocarcinoma. Clin Radiol 2020;75:478.e1-478.e11. [PMID: 32037002 DOI: 10.1016/j.crad.2019.12.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
69 Tummers WS, Farina-Sarasqueta A, Boonstra MC, Prevoo HA, Sier CF, Mieog JS, Morreau J, van Eijck CH, Kuppen PJ, van de Velde CJ, Bonsing BA, Vahrmeijer AL, Swijnenburg RJ. Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma. Oncotarget 2017;8:56816-28. [PMID: 28915633 DOI: 10.18632/oncotarget.18232] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
70 Sho M, Akahori T, Tanaka T, Kinoshita S, Nagai M, Tamamoto T, Ohbayashi C, Hasegawa M, Kichikawa K, Nakajima Y. Importance of resectability status in neoadjuvant treatment for pancreatic cancer. J Hepatobiliary Pancreat Sci 2015;22:563-70. [PMID: 25921623 DOI: 10.1002/jhbp.258] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
71 Combs SE. Individualized radiotherapy (iRT) concepts for locally advanced pancreatic cancer (LAPC): indications and prognostic factors. Langenbecks Arch Surg 2015;400:749-56. [DOI: 10.1007/s00423-015-1309-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
72 Kim SJ, Park JY, Hwang HS, Kang CM. Complete response of locally advanced left-sided pancreatic cancer after modified FOLFIRINOX chemotherapy followed by conversion surgery: A case report. Ann Hepatobiliary Pancreat Surg 2021;25:390-4. [PMID: 34402441 DOI: 10.14701/ahbps.2021.25.3.390] [Reference Citation Analysis]
73 Yoshitomi H, Takano S, Furukawa K, Takayashiki T, Kuboki S, Ohtsuka M. Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. Surg Today 2019;49:894-906. [PMID: 30949842 DOI: 10.1007/s00595-019-01804-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
74 Lee JC, Kim JW, Ahn S, Kim HW, Lee J, Kim YH, Paik KH, Kim J, Hwang JH. Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity. Eur J Cancer. 2017;76:125-133. [PMID: 28324747 DOI: 10.1016/j.ejca.2017.02.010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
75 Byrne JD, Jajja MR, Schorzman AN, Keeler AW, Luft JC, Zamboni WC, DeSimone JM, Yeh JJ. Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A 2016;113:2200-5. [PMID: 26858448 DOI: 10.1073/pnas.1600421113] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
76 Tang TY, Li X, Zhang Q, Guo CX, Zhang XZ, Lao MY, Shen YN, Xiao WB, Ying SH, Sun K, Yu RS, Gao SL, Que RS, Chen W, Huang DB, Pang PP, Bai XL, Liang TB. Development of a Novel Multiparametric MRI Radiomic Nomogram for Preoperative Evaluation of Early Recurrence in Resectable Pancreatic Cancer. J Magn Reson Imaging 2020;52:231-45. [PMID: 31867839 DOI: 10.1002/jmri.27024] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
77 Wu YHA, Oba A, Lin R, Watanabe S, Meguid C, Schulick RD, Del Chiaro M. Selecting surgical candidates with locally advanced pancreatic cancer: a review for modern pancreatology. J Gastrointest Oncol 2021;12:2475-83. [PMID: 34790408 DOI: 10.21037/jgo-21-119] [Reference Citation Analysis]
78 Chen X, Liu G, Wang K, Chen G, Sun J. Neoadjuvant radiation followed by resection versus upfront resection for locally advanced pancreatic cancer patients: a propensity score matched analysis. Oncotarget 2017;8:47831-40. [PMID: 28599299 DOI: 10.18632/oncotarget.18091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
79 Martin RCG 2nd. Multi-disciplinary management of locally advanced pancreatic cancer with irreversible electroporation. J Surg Oncol 2017;116:35-45. [PMID: 28475814 DOI: 10.1002/jso.24640] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
80 Tajima H, Makino I, Ohbatake Y, Nakanuma S, Hayashi H, Nakagawara H, Miyashita T, Takamura H, Ohta T. Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives. Oncol Lett 2017;13:3975-81. [PMID: 28599404 DOI: 10.3892/ol.2017.6008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
81 Xia BT, Fu B, Wang J, Kim Y, Ahmad SA, Dhar VK, Levinsky NC, Hanseman DJ, Habib DA, Wilson GC, Smith M, Olowokure OO, Kharofa J, Al Humaidi AH, Choe KA, Abbott DE, Ahmad SA. Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy? J Surg Oncol 2017;115:376-83. [DOI: 10.1002/jso.24538] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
82 Maurel J, Sánchez-Cabús S, Laquente B, Gaba L, Visa L, Fabregat J, Povés I, Roselló S, Díaz-Beveridge R, Martín-Richard M, Rodriguez J, Sabater L, Conill C, Cambray M, Reig A, Ayuso JR, Valls C, Ferrández A, Bombí JA, Ginés A, García-Albéniz X, Fernández-Cruz L. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial). Cancer Chemother Pharmacol 2018;82:935-43. [PMID: 30225601 DOI: 10.1007/s00280-018-3682-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
83 Okada K, Kawai M, Hirono S, Satoi S, Yanagimoto H, Ioka T, Miyazawa M, Shimizu A, Kitahata Y, Yamaue H. Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial. Cancer Chemother Pharmacol 2016;78:719-26. [PMID: 27501851 DOI: 10.1007/s00280-016-3121-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
84 Napolitano F, Formisano L, Giardino A, Girelli R, Servetto A, Santaniello A, Foschini F, Marciano R, Mozzillo E, Carratù AC, Cascetta P, De Placido P, De Placido S, Bianco R. Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. Cancers (Basel) 2019;11:E981. [PMID: 31337045 DOI: 10.3390/cancers11070981] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
85 Natsume S, Shimizu Y, Senda Y, Hijioka S, Matsuo K, Ito S, Komori K, Abe T, Hara K. Conversion surgery only for highly selected patients with unresectable pancreatic cancer: a satisfactory outcome in exchange for a lower resection rate. Surg Today 2019;49:670-7. [PMID: 30730003 DOI: 10.1007/s00595-019-01776-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
86 Creasy JM, Goldman DA, Dudeja V, Lowery MA, Cercek A, Balachandran VP, Allen PJ, DeMatteo RP, Kingham TP, D'Angelica MI, Jarnagin WR. Systemic Chemotherapy Combined with Resection for Locally Advanced Gallbladder Carcinoma: Surgical and Survival Outcomes. J Am Coll Surg. 2017;224:906-916. [PMID: 28216422 DOI: 10.1016/j.jamcollsurg.2016.12.058] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
87 Barenboim A, Lahat G, Geva R, Nachmany I, Nakache R, Goykhman Y, Brazowski E, Rosen G, Isakov O, Wolf I, Klausner JM, Lubezky N. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. European Journal of Surgical Oncology 2018;44:1619-23. [DOI: 10.1016/j.ejso.2018.07.057] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 12.8] [Reference Citation Analysis]
88 Saito T, Ishido K, Kudo D, Kimura N, Wakiya T, Nakayama Y, Hakamada K. Combination therapy with gemcitabine and nab-paclitaxel for locally advanced unresectable pancreatic cancer. Mol Clin Oncol 2017;6:963-7. [PMID: 28588798 DOI: 10.3892/mco.2017.1251] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
89 Vitolo V, Cobianchi L, Brugnatelli S, Barcellini A, Peloso A, Facoetti A, Vanoli A, Delfanti S, Preda L, Molinelli S, Klersy C, Fossati P, Orecchia R, Valvo F. Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm study. BMC Cancer 2019;19:922. [PMID: 31521134 DOI: 10.1186/s12885-019-6108-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
90 Attard JA, Farrugia A, Pathanki A, Roberts KJ, Dasari B, Isaac J, Ma YT, Chatzizacharias NA. Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent: A Systematic Review. Pancreas 2020;49:1264-75. [PMID: 33122513 DOI: 10.1097/MPA.0000000000001694] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
91 Raufi AG, Manji GA, Chabot JA, Bates SE. Neoadjuvant Treatment for Pancreatic Cancer. Seminars in Oncology 2019;46:19-27. [DOI: 10.1053/j.seminoncol.2018.12.002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 14.3] [Reference Citation Analysis]
92 Alemi F, Alseidi A, Scott Helton W, Rocha FG. Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma. Curr Probl Surg 2015;52:362-98. [PMID: 26363649 DOI: 10.1067/j.cpsurg.2015.07.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
93 Kawai M, Hirono S, Okada K, Miyazawa M, Shimizu A, Kitahata Y, Kobayashi R, Ueno M, Hayami S, Tanioka K, Yamaue H. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer. Surgery 2019;165:1151-60. [DOI: 10.1016/j.surg.2018.12.015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
94 Takahashi S. How to treat borderline resectable pancreatic cancer: current challenges and future directions. Japanese Journal of Clinical Oncology 2018;48:205-13. [DOI: 10.1093/jjco/hyx191] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
95 Oba A, Ho F, Bao QR, Al-Musawi MH, Schulick RD, Del Chiaro M. Neoadjuvant Treatment in Pancreatic Cancer. Front Oncol. 2020;10:245. [PMID: 32185128 DOI: 10.3389/fonc.2020.00245] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 14.5] [Reference Citation Analysis]
96 Martin RC. Management of Locally Advanced Pancreatic Cancer. Surgical Clinics of North America 2016;96:1371-89. [DOI: 10.1016/j.suc.2016.07.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
97 Indolfi L, Ligorio M, Ting DT, Xega K, Tzafriri AR, Bersani F, Aceto N, Thapar V, Fuchs BC, Deshpande V, Baker AB, Ferrone CR, Haber DA, Langer R, Clark JW, Edelman ER. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. Biomaterials 2016;93:71-82. [PMID: 27082874 DOI: 10.1016/j.biomaterials.2016.03.044] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
98 Kang MJ, Jang J, Kwon W, Kim S. Clinical significance of defining borderline resectable pancreatic cancer. Pancreatology 2018;18:139-45. [DOI: 10.1016/j.pan.2017.12.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
99 Ahmed SA, Atta H, Hassan RA. The utility of Multi-Detector Computed Tomography criteria after neoadjuvant therapy in Borderline Resectable Pancreatic cancer: Prospective, bi-institutional study. Eur J Radiol 2021;139:109685. [PMID: 33819805 DOI: 10.1016/j.ejrad.2021.109685] [Reference Citation Analysis]
100 Allan BJ, Novak SM, Hogg ME, Zeh HJ. Robotic vascular resections during Whipple procedure. J Vis Surg 2018;4:13. [PMID: 29445599 DOI: 10.21037/jovs.2017.12.15] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
101 Hackert T, Ulrich A, Büchler MW. Borderline resectable pancreatic cancer. Cancer Lett 2016;375:231-7. [PMID: 26970276 DOI: 10.1016/j.canlet.2016.02.039] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
102 Ahn DH, Williams TM, Goldstein DA, El-Rayes B, Bekaii-Saab T. Adjuvant therapy for pancreas cancer in an era of value based cancer care. Cancer Treat Rev 2016;42:10-7. [PMID: 26620819 DOI: 10.1016/j.ctrv.2015.11.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
103 Lakatos G, Petranyi A, Szűcs A, Nehéz L, Harsanyi L, Hegyi P, Bodoky G. Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience. Pathol Oncol Res 2017;23:753-9. [PMID: 28062950 DOI: 10.1007/s12253-016-0176-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
104 Bednar F, Zenati MS, Steve J, Winters S, Ocuin LM, Bahary N, Hogg ME, Zeh HJ 3rd, Zureikat AH. Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes? Ann Surg Oncol 2017;24:1406-13. [PMID: 27896518 DOI: 10.1245/s10434-016-5707-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
105 Benzing C, Hau H, Atanasov G, Broschewitz J, Krenzien F, Bartels M, Wiltberger G. Outcome and complications of combined liver and pancreas resections: a retrospective analysis. Acta Chirurgica Belgica 2016;116:340-5. [DOI: 10.1080/00015458.2016.1186962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
106 Polish A, Joseph NE, Marsh RW. Pathologic Response to Primary Systemic Therapy With FOLFIRINOX in Patients With Resectable Pancreatic Cancer. Am J Clin Oncol 2019;42:761-6. [PMID: 31569128 DOI: 10.1097/COC.0000000000000601] [Reference Citation Analysis]
107 Bratlie SO, Wennerblom J, Vilhav C, Persson J, Rangelova E. Resectable, borderline, and locally advanced pancreatic cancer-"the good, the bad, and the ugly" candidates for surgery? J Gastrointest Oncol 2021;12:2450-60. [PMID: 34790406 DOI: 10.21037/jgo-2020-slapc-04] [Reference Citation Analysis]
108 Lillemoe KD. Invited Commentary on "Tumor-Vessel Relationships in Pancreatic Ductal Adenocarcinoma at Multidetector CT," with Response from Dr Zaky and Colleagues. Radiographics 2017;37:113-5. [PMID: 28076018 DOI: 10.1148/rg.2017160205] [Reference Citation Analysis]
109 Lee RC, Kanhere H, Trochsler M, Broadbridge V, Maddern G, Price TJ. Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases? World J Gastrointest Oncol 2018; 10(8): 211-220 [PMID: 30147847 DOI: 10.4251/wjgo.v10.i8.211] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
110 Reilley MJ, Shroff R, Varadhachary GR. Adjuvant/Perioperative Therapy in Pancreatic and Periampullary Cancer. Indian J Surg 2015;77:403-8. [PMID: 26722204 DOI: 10.1007/s12262-015-1361-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
111 Kang H, Jo JH, Lee HS, Chung MJ, Bang S, Park SW, Song SY, Park JY. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. World J Gastrointest Oncol 2018; 10(11): 421-430 [PMID: 30487953 DOI: 10.4251/wjgo.v10.i11.421] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
112 Soer EC, Verbeke CS. Pathology reporting of margin status in locally advanced pancreatic cancer: challenges and uncertainties. J Gastrointest Oncol 2021;12:2512-20. [PMID: 34790412 DOI: 10.21037/jgo-20-391] [Reference Citation Analysis]
113 Ulusakarya A, Teyar N, Karaboué A, Haydar M, Krimi S, Biondani P, Gumus Y, Chebib A, Almohamad W, Morère JF. Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma. Medicine (Baltimore) 2019;98:e15341. [PMID: 31008993 DOI: 10.1097/MD.0000000000015341] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
114 Dhir M, Malhotra GK, Sohal DPS, Hein NA, Smith LM, O'Reilly EM, Bahary N, Are C. Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. World J Surg Oncol. 2017;15:183. [PMID: 29017581 DOI: 10.1186/s12957-017-1240-2] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 13.0] [Reference Citation Analysis]
115 Lee SY, Sissoko M, Hartshorn KL. Update on the Management of Pancreatic Cancer in Older Adults. Curr Oncol Rep 2016;18:60. [PMID: 27492426 DOI: 10.1007/s11912-016-0547-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
116 Giommoni E, Maiello E, Vaccaro V, Rondini E, Vivaldi C, Tortora G, Toppo L, Giordano G, Latiano TP, Lamperini C, Pillozzi S, Boni L, Antonuzzo L, Di Costanzo F. Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study). Curr Oncol 2021;28:1761-72. [PMID: 34066784 DOI: 10.3390/curroncol28030164] [Reference Citation Analysis]
117 Brasoveanu V, Romanescu D, Barbu I, Balescu I, Bacalbasa N. Pancreatectomy With Arterial and Portal Vein Reconstruction for Locally Advanced Pancreatic Cancer - A Case Report and Literature Review. In Vivo 2020;34:2791-5. [PMID: 32871816 DOI: 10.21873/invivo.12104] [Reference Citation Analysis]
118 Cecchini M, Miccio JA, Pahade J, Lacy J, Salem RR, Johnson SB, Blakaj A, Stein S, Kortmansky JS, Johung KL. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer. Pancreas 2020;49:904-11. [PMID: 32658074 DOI: 10.1097/MPA.0000000000001592] [Reference Citation Analysis]
119 Petrucciani N, Debs T, Nigri G, Giannini G, Sborlini E, Kassir R, Ben Amor I, Iannelli A, Valabrega S, D'Angelo F, Gugenheim J, Ramacciato G. Pancreatectomy combined with multivisceral resection for pancreatic malignancies: is it justified? Results of a systematic review. HPB (Oxford). 2018;20:3-10. [PMID: 28943396 DOI: 10.1016/j.hpb.2017.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
120 Amodeo S, Masi A, Melis M, Ryan T, Hochster HS, Cohen DJ, Chandra A, Pachter HL, Newman E. Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation. J Gastrointest Oncol 2018;9:922-35. [PMID: 30505595 DOI: 10.21037/jgo.2017.10.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
121 Ocuin LM, Miller-Ocuin JL, Novak SM, Bartlett DL, Marsh JW, Tsung A, Lee KK, Hogg ME, Zeh HJ, Zureikat AH. Robotic and open distal pancreatectomy with celiac axis resection for locally advanced pancreatic body tumors: a single institutional assessment of perioperative outcomes and survival. HPB (Oxford) 2016;18:835-42. [PMID: 27506992 DOI: 10.1016/j.hpb.2016.05.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
122 Shaib WL, Ip A, Cardona K, Alese OB, Maithel SK, Kooby D, Landry J, El-Rayes BF. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer. Oncologist 2016;21:178-87. [PMID: 26834159 DOI: 10.1634/theoncologist.2015-0316] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
123 Vitello DJ, Bentrem DJ. A review of response in neoadjuvant therapy for exocrine pancreatic cancer. J Surg Oncol 2021;123:1449-59. [PMID: 33831249 DOI: 10.1002/jso.26369] [Reference Citation Analysis]
124 Sugimoto M, Takahashi N, Farnell MB, Smyrk TC, Truty MJ, Nagorney DM, Smoot RL, Chari ST, Carter RE, Kendrick ML. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis. J Surg Oncol. 2019;120:976-984. [PMID: 31452208 DOI: 10.1002/jso.25681] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
125 Garnier J, Ewald J, Marchese U, Gilabert M, Moureau-Zabotto L, Giovannini M, Poizat F, Delpero JR, Turrini O. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen. Eur J Surg Oncol 2020;46:1510-5. [PMID: 32146053 DOI: 10.1016/j.ejso.2020.02.037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Narayanan G, Bilimoria MM, Hosein PJ, Su Z, Mortimer KM, Martin RCG 2nd. Multicenter randomized controlled trial and registry study to assess the safety and efficacy of the NanoKnife® system for the ablation of stage 3 pancreatic adenocarcinoma: overview of study protocols. BMC Cancer 2021;21:785. [PMID: 34233640 DOI: 10.1186/s12885-021-08474-4] [Reference Citation Analysis]
127 Choi JG, Nipp RD, Tramontano A, Ali A, Zhan T, Pandharipande P, Dowling EC, Ferrone CR, Hong TS, Schrag D, Fernandez-Del Castillo C, Ryan DP, Kong CY, Hur C. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. Oncologist 2019;24:945-54. [PMID: 30559125 DOI: 10.1634/theoncologist.2018-0114] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
128 Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Nakagawa N, Takahashi S, Sueda T. Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact. Cancer Chemother Pharmacol 2017;79:37-47. [PMID: 27878355 DOI: 10.1007/s00280-016-3199-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
129 Vaccaro V, Sperduti I, Vari S, Bria E, Melisi D, Garufi C, Nuzzo C, Scarpa A, Tortora G, Cognetti F, Reni M, Milella M. Metastatic pancreatic cancer: Is there a light at the end of the tunnel? World J Gastroenterol 2015; 21(16): 4788-4801 [PMID: 25944992 DOI: 10.3748/wjg.v21.i16.4788] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 44] [Article Influence: 6.4] [Reference Citation Analysis]
130 Yamada S, Fujii T, Yokoyama Y, Kawashima H, Maeda O, Suzuki K, Okada T, Ono E, Yamaguchi J, Takano N, Takami H, Hayashi M, Niwa Y, Hirooka Y, Ito Y, Naganawa S, Ando Y, Nagino M, Goto H, Kodera Y. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer. Cancer Chemother Pharmacol 2018;81:815-21. [PMID: 29502139 DOI: 10.1007/s00280-018-3554-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
131 Lambert A, Gavoille C, Conroy T. Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions. Therap Adv Gastroenterol 2017;10:631-45. [PMID: 28835777 DOI: 10.1177/1756283X17713879] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
132 Coveler AL, Herman JM, Simeone DM, Chiorean EG. Localized Pancreatic Cancer: Multidisciplinary Management. Am Soc Clin Oncol Educ Book 2016;35:e217-26. [PMID: 27249726 DOI: 10.1200/EDBK_160827] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
133 Imamura M, Nagayama M, Kyuno D, Ota S, Murakami T, Kimura A, Yamaguchi H, Kato T, Kimura Y, Takemasa I. Perioperative Predictors of Early Recurrence for Resectable and Borderline-Resectable Pancreatic Cancer. Cancers (Basel) 2021;13:2285. [PMID: 34064540 DOI: 10.3390/cancers13102285] [Reference Citation Analysis]
134 Kang G, Hu M, Ren H, Wang J, Cheng X, Li R, Yuan B, Balan Y, Bai Z, Huang H. VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo. Cancer Biol Med 2021:j. [PMID: 33830713 DOI: 10.20892/j.issn.2095-3941.2020.0568] [Reference Citation Analysis]
135 Tsiotos GG, Ballian N, Michelakos T, Milas F, Ziogou P, Papaioannou D, Salla C, Athanasiadis I, Razis E, Stavridi F, Psomas M. Portal-Mesenteric Vein Resection in Borderline Pancreatic Cancer; 33 Month-Survival in Patients with Good Performance Status. J Pancreat Cancer 2019;5:43-50. [PMID: 31559380 DOI: 10.1089/pancan.2019.0013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
136 Javed AA, Wright MJ, Siddique A, Blair AB, Ding D, Burkhart RA, Makary M, Cameron JL, Narang A, Herman J, Zheng L, Laheru D, Weiss MJ, Wolfgang C, He J. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. J Gastrointest Surg 2019;23:112-21. [PMID: 30242644 DOI: 10.1007/s11605-018-3966-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
137 Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? J Surg Oncol. 2016;114:587-596. [PMID: 27444658 DOI: 10.1002/jso.24375] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
138 Levy MJ, Alberts SR, Bamlet WR, Burch PA, Farnell MB, Gleeson FC, Haddock MG, Kendrick ML, Oberg AL, Petersen GM, Takahashi N, Chari ST. EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer. Gastrointest Endosc 2017;86:161-9. [PMID: 27889543 DOI: 10.1016/j.gie.2016.11.014] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
139 Cloyd JM, Katz MH, Prakash L, Varadhachary GR, Wolff RA, Shroff RT, Javle M, Fogelman D, Overman M, Crane CH, Koay EJ, Das P, Krishnan S, Minsky BD, Lee JH, Bhutani MS, Weston B, Ross W, Bhosale P, Tamm EP, Wang H, Maitra A, Kim MP, Aloia TA, Vauthey JN, Fleming JB, Abbruzzese JL, Pisters PW, Evans DB, Lee JE. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. J Gastrointest Surg. 2017;21:164-174. [PMID: 27778257 DOI: 10.1007/s11605-016-3265-1] [Cited by in Crossref: 92] [Cited by in F6Publishing: 82] [Article Influence: 15.3] [Reference Citation Analysis]
140 Kobayashi N, Shimamura T, Tokuhisa M, Goto A, Endo I, Ichikawa Y. Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure. Medicine (Baltimore). 2017;96:e6769. [PMID: 28489753 DOI: 10.1097/md.0000000000006769] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]